Lapatinib Stada

Lapatinib, the active ingredient in Lapatinib Stada, is a tyrosine kinase inhibitor presented as a tablet for oral use. It blocks HER2 and EGFR signaling and is indicated for the treatment of HER2‑positive metastatic breast cancer and HER2‑positive advanced gastric or gastro‑oesophageal junction adenocarcinoma in adult patients who require systemic therapy under specialist oncology care.

GNH USA supplies Lapatinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with reliable quality assurance and regulatory compliance.

Lapatinib targets HER2 and EGFR pathways in HER2‑positive cancers.

HER2‑positive metastatic breast cancer: improves disease control when combined with chemotherapy. HER2‑positive advanced gastric or gastro‑oesophageal junction adenocarcinoma: extends survival after prior therapy. HER2‑positive breast cancer in combination with capecitabine: provides an oral targeted option alongside chemotherapy.

Lapatinib may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Diarrhea - Rash or skin irritation - Nausea - Fatigue - Vomiting - Headache

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Cardiac dysfunction, including decreased left ventricular ejection fraction - Interstitial lung disease or severe pulmonary toxicity

When prescribing Lapatinib, clinicians should observe several safety measures.

Cardiac monitoring: assess baseline and periodic left ventricular function. Liver function tests: monitor transaminases and bilirubin regularly. Skin assessment: watch for severe rash or Stevens‑Johnson‑like reactions. Avoid in severe diarrhea: discontinue if uncontrolled. Dose adjustment in hepatic impairment: consider reduced dose. Store at ambient temperature: keep in the original pack, protect from moisture.

Lapatinib is metabolized primarily by CYP3A4, leading to clinically relevant drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lapatinib exposure. - QT‑prolonging agents (e.g., sotalol, quinidine): may raise risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Warfarin: may alter anticoagulant effect; monitor INR. - Oral contraceptives: may reduce hormonal efficacy; advise alternative contraception.